Reference number(s)
3167-H

SPECIALTY QUANTITY LIMIT PROGRAM

ROZLYTREK (entrectinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Rozlytrek 100mg capsules	150 per 30 days	• Adult : 600 mg (three 200mg capsules) once daily • Pediatric patients 12 years and older: • BSA greater than 1.50 m^2: 600 mg once daily • BSA 1.11 to 1.50 m^2: 500 mg once daily • BSA 0.91 to 1.10 m^2: 400 mg once daily • Dosage modifications for adverse reactions and drug interactions may be required.
Rozlytrek 200mg capsules	90 per 30 days	

III. REFERENCES

1. Rozlytrek [package insert]. South San Francisco, CA: Genentech, Inc. August 2019.

CVS caremark™